Nano-Pulse Stimulation Therapy in Oncology.

IF 1.6 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Bioelectricity Pub Date : 2024-06-12 eCollection Date: 2024-06-01 DOI:10.1089/bioe.2024.0009
Richard Nuccitelli, Amanda McDaniel
{"title":"Nano-Pulse Stimulation Therapy in Oncology.","authors":"Richard Nuccitelli, Amanda McDaniel","doi":"10.1089/bioe.2024.0009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nano-Pulse Stimulation (NPS) therapy applies electric pulses in the nanosecond domain to initiate regulated cell death in the treated tissues. This nonthermal therapy has been used to treat a wide range of murine tumors and has been shown to activate the immune system to inhibit the growth of rechallenge tumors, as well as untreated, abscopal tumors when accompanied by the injection of immune system stimulants into the treated tumors. Clinical trials have begun using NPS to treat basal cell carcinoma and hepatocellular carcinoma.</p><p><strong>Methods: </strong>Murine tumors can be easily imaged when the tumor cells are injected intradermally so that they grow within the mouse skin. Pulling the skin over a translucent light post shines light through the skin and makes it easy to treat the tumor and identify the treatment zone.</p><p><strong>Results: </strong>Original research using murine tumor models is described, including melanoma, squamous cell carcinoma, lung carcinoma, breast carcinoma, and pancreatic carcinoma. The energy required to ablate these tumors has been determined with pancreatic carcinoma and lung carcinoma exhibiting 90% ablation with 240 mJ/mm<sup>3</sup>, lung carcinoma and squamous cell carcinoma requiring 360 mJ/mm<sup>3</sup>, and melanoma requiring 480 mJ/mm<sup>3</sup>. NPS therapy initiated a variable immune response indicated by the rejection of injected rechallenge tumor cells with melanoma and hepatocellular carcinoma exhibiting the strongest response and lung carcinoma, the weakest response. Following the original research data, a review of human clinical trials using NPS therapy is presented.</p><p><strong>Conclusions: </strong>NPS therapy offers a nonthermal, drug-free approach for oncology, which is limited only by applying energy to the tumor. This new immunogenic modality is just beginning to be applied in the clinic. The 87% efficacy of the first large clinical trial conducted by several medical personnel is impressive and indicates that NPS is an effective new modality for cancer treatment.</p>","PeriodicalId":29923,"journal":{"name":"Bioelectricity","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioelectricity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/bioe.2024.0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Nano-Pulse Stimulation (NPS) therapy applies electric pulses in the nanosecond domain to initiate regulated cell death in the treated tissues. This nonthermal therapy has been used to treat a wide range of murine tumors and has been shown to activate the immune system to inhibit the growth of rechallenge tumors, as well as untreated, abscopal tumors when accompanied by the injection of immune system stimulants into the treated tumors. Clinical trials have begun using NPS to treat basal cell carcinoma and hepatocellular carcinoma.

Methods: Murine tumors can be easily imaged when the tumor cells are injected intradermally so that they grow within the mouse skin. Pulling the skin over a translucent light post shines light through the skin and makes it easy to treat the tumor and identify the treatment zone.

Results: Original research using murine tumor models is described, including melanoma, squamous cell carcinoma, lung carcinoma, breast carcinoma, and pancreatic carcinoma. The energy required to ablate these tumors has been determined with pancreatic carcinoma and lung carcinoma exhibiting 90% ablation with 240 mJ/mm3, lung carcinoma and squamous cell carcinoma requiring 360 mJ/mm3, and melanoma requiring 480 mJ/mm3. NPS therapy initiated a variable immune response indicated by the rejection of injected rechallenge tumor cells with melanoma and hepatocellular carcinoma exhibiting the strongest response and lung carcinoma, the weakest response. Following the original research data, a review of human clinical trials using NPS therapy is presented.

Conclusions: NPS therapy offers a nonthermal, drug-free approach for oncology, which is limited only by applying energy to the tumor. This new immunogenic modality is just beginning to be applied in the clinic. The 87% efficacy of the first large clinical trial conducted by several medical personnel is impressive and indicates that NPS is an effective new modality for cancer treatment.

肿瘤学中的纳米脉冲刺激疗法
背景:纳米脉冲刺激疗法(NPS)应用纳秒级电脉冲来启动受治疗组织中的调节性细胞死亡。这种非热疗法已被用于治疗多种小鼠肿瘤,并被证明能激活免疫系统,抑制再发肿瘤的生长,以及在治疗肿瘤的同时注射免疫系统刺激剂,抑制未经治疗的腹腔肿瘤的生长。使用 NPS 治疗基底细胞癌和肝细胞癌的临床试验已经开始:方法:将肿瘤细胞注射到小鼠皮内,使其在小鼠皮肤内生长,就可以很容易地对小鼠肿瘤进行成像。将皮肤拉到半透明灯柱上,光线就会透过皮肤照射到肿瘤上,这样就很容易治疗肿瘤并确定治疗区域:结果:介绍了利用小鼠肿瘤模型进行的原创性研究,包括黑色素瘤、鳞状细胞癌、肺癌、乳腺癌和胰腺癌。确定了消融这些肿瘤所需的能量,其中胰腺癌和肺癌的消融率为 90%,240 mJ/mm3;肺癌和鳞状细胞癌的消融率为 360 mJ/mm3;黑色素瘤的消融率为 480 mJ/mm3。NPS 疗法会引发不同的免疫反应,表现为对注射的再挑战肿瘤细胞的排斥反应,其中黑色素瘤和肝细胞癌的反应最强,而肺癌的反应最弱。在原始研究数据之后,对使用 NPS 疗法的人体临床试验进行了回顾:结论:NPS疗法为肿瘤学提供了一种无热、无药的方法,其局限性仅在于对肿瘤施加能量。这种新型免疫疗法刚刚开始应用于临床。由多名医务人员进行的首次大型临床试验取得了 87% 的疗效,令人印象深刻,这表明 NPS 是一种有效的癌症治疗新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioelectricity
Bioelectricity Multiple-
CiteScore
3.40
自引率
4.30%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信